Bioqube Ventures is a specialist life sciences investment firm. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.

Bioqube Ventures launched in 2020 its first independent fund “Bioqube Factory Fund I”.

… An early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.

… A fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. 

… A hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.

Bioqube Ventures

Fellowship opportunity! Do you have a scientific background, are you passionate about developing therapeutics and eager to learn more about what makes venture capital tick in biotech? Then this 6-month Fellowship program at Bioqube might be the right fit for you! Find out more in the description below ⤵️ #vc #biotech #fellowship

Exciting update from our portfolio company @Bicara Therapeutics at @ESMO !

Welcome Krishna Polu ! What a great addition to our Bioqube Ventures team! Proud to be part of this family!

Exciting update from Bioqube portfolio company Bicara Therapeutics, congratulations to the team on unveiling their manuscript. Read all about it below. #aacr23 #BFFI
https://lnkd.in/eMAwSuya

Bioqube Ventures is pleased to welcome Bicara Therapeutics to our portfolio, a clinical-stage biotech advancing its lead program BCA101 and its pipeline of investigational candidates to treat solid tumor cancers.

https://lnkd.in/efJAtW9Q

Domain Not Resolving

U.S. Server Location

Pound Sterling

Amazon Route 53

Business Management

Birgit Zech

Sakae Asanuma

Karin Kleinhans

Mathieu Bollen

Nicholas Tonks

Debora Dumont

Therese Liechtenstein

Claus Schalper

Simone Botti

Co-Founder, Chief Executive Officer

Edward Holson

Chief Scientific Officer and President US

Gerhard Müller

Co-Founder, Chief Scientific Officer

M Ventures Portfolio Companies

Biotechnology Companies With Fewer Than 10 Employees (Top 10K)

Inkef Portfolio Companies

Private Europe Companies (Top 10K)

Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications

Seed Round - Anavo Therapeutics

Inkef

M Ventures

Taiho Ventures

Leiden

Zuid-Holland

The Netherlands

Europe

Anavo Therapeutics

Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US

Anavo Therapeutics Strengthens Management Team

Anavo Therapeutics Raises €8.5M; Extends Seed Round to €28M

Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic

Anavo Therapeutics–McDermott C: board, 202112– Board Chairman main org Primmune Therapeutics Inc

Anavo Therapeutics–Bioqube Ventures: investment, 202104 seed financing round totalling €20m incl co-investor Bioqube Ventures

Anavo Therapeutics–MacDougall Advisors: public relations, 202104 service existent by MacDougall

Anavo Therapeutics wants Big Pharma to dust off the shelves in search of phosphatase drugs

Anavo Therapeutics closes $24M seed round to drug the phosphatome

A platform for drug discovery targeting phosphatases, previously considered undruggable, using allosteric modulators.

Development of first-in-class therapeutic programs targeting phosphatases for various indications, including cancer.

Support for partners in establishing pipelines for phosphatase-targeted therapies across a range of therapeutic indications.

A research and development hub in Heidelberg, Germany, to leverage resources for advancing the IGNITE platform and therapeutic programs.

India

Asia

Bangladesh

Mexico

North America

Rappta Therapeutics is a competitor of Anavo Therapeutics in the field of allosteric modulators for phosphatases.

Rappta Therapeutics

Anavo Therapeutics is a biotechnology company focused on the development of allosteric modulators for phosphatases, aiming to create a pipeline of novel therapeutics for various diseases.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	May 9, 2024 6:39 AM	047ca67f
public peers	general	May 9, 2024 6:39 AM	677ba0c2
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 9, 2024 6:39 AM	f06ecb10
company summary	general
signals	general
crunchbase trigger	general	Dec 4, 2024 8:54 AM	4e8595b6
crunchbase profile	general	Dec 4, 2024 12:36 PM	3c0dba55
li profile	general	May 9, 2024 6:39 AM	15bfa80a
translate crunchbase fundingrounds	general	Dec 4, 2024 1:36 PM	67560e3d
peers	general
news basic	general	May 9, 2024 6:39 AM	e9a9ea55
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:BIOQUBEVENTURES

Anavo Therapeutics